Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Galapagos NV ADR
(NQ:
GLPG
)
26.67
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Galapagos NV ADR
< Previous
1
2
3
4
Next >
GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
June 25, 2024
GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
April 01, 2024
BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets.
Via
Benzinga
European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments
January 03, 2024
On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: GLPG).
Via
Benzinga
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
December 13, 2023
GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023.
Via
InvestorPlace
8 Analysts Have This to Say About Galapagos
July 17, 2023
Via
Benzinga
Where Galapagos Stands With Analysts
June 12, 2023
Via
Benzinga
JP Morgan Maintains Neutral Rating for Galapagos: Here's What You Need To Know
May 31, 2023
Via
Benzinga
Earnings Outlook For Galapagos
May 03, 2023
Via
Benzinga
Earnings Preview For Galapagos
February 23, 2023
Via
Benzinga
Where Galapagos Stands With Analysts
November 07, 2022
Galapagos (NASDAQ:GLPG) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Where Galapagos Stands With Analysts
September 09, 2022
Analysts have provided the following ratings for Galapagos (NASDAQ:GLPG) within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
May 08, 2023
Via
Benzinga
BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
February 24, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients
February 10, 2023
Via
Benzinga
Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field
June 22, 2022
Via
Benzinga
Galapagos In-licenses Inflammatory Bowel Disease Drug Targets From Scipher Medicine
May 24, 2022
Via
Benzinga
Why Galapagos Stock Is Falling Today
February 09, 2023
Galapagos NV (NASDAQ: GLPG) announced the topline results from the DIVERSITY Phase 3 trial of filgotinib during induction and maintenance treatment of biologic-naïve and biologic-experienced patients...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
January 23, 2023
Via
Benzinga
Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories
December 20, 2022
Benzinga
Via
Benzinga
On A Mission As Top European Player, Galapagos Looks For Acquisition Targets
December 20, 2022
Galapagos NV (NASDAQ: GLPG) is reportedly looking for M&A deals with companies with products still in the preclinical or early stage of development.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022
November 07, 2022
Upgrades
Via
Benzinga
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
October 31, 2022
Via
Benzinga
Expert Ratings for Galapagos
October 13, 2022
Over the past 3 months, 4 analysts have published their opinion on Galapagos (NASDAQ:GLPG) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
3 Biotech Stocks to Sell in October
September 29, 2022
These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market.
Via
InvestorPlace
Lyft, DoorDash, Expedia And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
August 05, 2022
Atlas Corp. (NYSE: ATCO) rose 21.4% to $14.06 in pre-market trading after the company said it received a non-binding proposal from Poseidon Acquisition Corp. to acquire all outstanding common shares of...
Via
Benzinga
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
June 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Upgrades
Via
Benzinga
RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value
May 09, 2022
RBC Capital Markets views Galapagos' NV (NASDAQ: GLPG) Q1 Jyseleca revenues in line as the story focuses on whether new leadership can unlock value from GLPG's ample balance sheet.
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
February 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.